Products for Research Use Only
RegisterLogin

Abemaciclib metabolite M18

CAT: 0804-HY-126534-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-126534-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].
CAS Number
2704316-81-2
Product Name Alternative
LSN3106729
UNSPSC
12352005
Target
CDK; Ligands for Target Protein for PROTAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/abemaciclib-metabolite-m18.html
Purity
98.01
Solubility
DMSO : 7.69 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
FC(C=N1)=C(C2=CC(N(C(C)C)C(CO)=N3)=C3C(F)=C2)N=C1NC4=NC=C(C=C4)CN5CCNCC5
Molecular Formula
C25H28F2N8O
Molecular Weight
494.54
References & Citations
[1]Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1.|[2]Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study.|[3]Palaniappan, et al. Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res. 2016-7-15; 76 (14_Supplement) : CT153. |[4]Goel S, et al. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018 Nov;28 (11) :911-925. |[5]Heckler M, et al. Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021 Oct;11 (10) :2564-2581. |[6]Heckler M, et al. Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021 Oct;11 (10) :2564-2581.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4; CDK6
Citation 01
Indonesian Journal of Pharmaceutics. 2025.|J Pharm Biomed Anal. 2021 Sep 5:203:114225.

Related Products

CatalogName
HY-128669-01Abemaciclib metabolite M2
HY-129336-01Abemaciclib metabolite M20
HY-128669R-01Abemaciclib metabolite M2 (Standard)
HY-129336SAbemaciclib metabolite M20-d8
HY-128669SAbemaciclib metabolite M2-d6
HY-16297A-01Abemaciclib
HY-W728130-01Abemaciclib-d5
HY-16297AS-01Abemaciclib-d8
HY-16297-01Abemaciclib (methanesulfonate)
HY-16297AR-01Abemaciclib (Standard)

Alternative Products

CatalogName
MBS5815953Abemaciclib metabolite M18
AR-A08021-01Abemaciclib M2 Metabolite
C04736Abemaciclib metabolite M2
MBS3614750-01Abemaciclib metabolite M20
FE103812-01Abemaciclib

Popular Products